Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction

Young Hoon Jeong, Won Jang Kim, Duk Woo Park, Bong Ryong Choi, Seung Whan Lee, Young Hak Kim, Cheol Whan Lee, Myeongki Hong, Jae Joong Kim, Seong Wook Park, Seung Jung Park

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The angiographic 'no-reflow' phenomenon after primary percutaneous coronary intervention (PPCI) is associated with a poor short-term and long-term clinical prognosis of ST-elevation myocardial infarction (STEMI). Although the increasing use of primary drug-eluting stent (DES) deployment for STEMI resulted in reduced adverse clinical outcomes, the prevalence of no-reflow has been unchanged. The purpose of our study was to evaluate the predictors for no-reflow for STEMI and identify such high-risk patients in the DES era. Methods: The study prospectively enrolled 300 consecutive STEMI patients (80% men; 57 ± 11 years) who underwent PPCI within 12 h of symptom onset. The no-reflow phenomenon was defined as an angiographic outcome of Thrombolysis In Myocardial Infarction (TIMI) grade < 3 without accompanying mechanical factors. Results: Compared to normal reflow patients, no-reflow patients (n = 15, 5% of the total study population) were older (64 ± 13 vs. 57 ±11 years; P = 0.019), transferred to hospital later (7.1 ± 3.2 vs. 4.5 ± 3.8 h; P = 0.011), and had a higher TIMI risk score (5.5 ± 2.0 vs. 3.8 ± 2.2; P = 0.004). B-type natriuretic peptide (BNP), high sensitivity C-reactive protein, and serum creatinine levels were higher in the no-reflow than the normal reflow group. Multivariate analysis (including clinical, angiographic and procedural variables with a P < 0.2 in univariate analysis) showed that high BNP level on admission was the only independent predictor of no-reflow. The area under the receiver-operating characteristics curve analysis value for BNP was 0.786. BNP ≥ 90 pg/ml showed a sensitivity of 80% and a specificity of 70% for predicting no-reflow after primary DES implantation (OR 14.953, 95% CI 3.131-71.419, P = 0.001). Conclusions: Angiographic 'no-reflow' phenomenon after primary DES implantation for STEMI can be predicted by BNP levels on admission. BNP-guided approach may be useful in identifying patients at high risk of the no-reflow phenomenon after primary stenting.

Original languageEnglish
Pages (from-to)175-181
Number of pages7
JournalInternational Journal of Cardiology
Volume141
Issue number2
DOIs
Publication statusPublished - 2010 May 28

Fingerprint

No-Reflow Phenomenon
Drug-Eluting Stents
Brain Natriuretic Peptide
Serum
Percutaneous Coronary Intervention
Myocardial Infarction
ROC Curve
C-Reactive Protein
ST Elevation Myocardial Infarction
Creatinine
Multivariate Analysis
Population

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Jeong, Young Hoon ; Kim, Won Jang ; Park, Duk Woo ; Choi, Bong Ryong ; Lee, Seung Whan ; Kim, Young Hak ; Lee, Cheol Whan ; Hong, Myeongki ; Kim, Jae Joong ; Park, Seong Wook ; Park, Seung Jung. / Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction. In: International Journal of Cardiology. 2010 ; Vol. 141, No. 2. pp. 175-181.
@article{ccb91b9f74054cf08b0cc7d3a1b40a70,
title = "Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction",
abstract = "Background: The angiographic 'no-reflow' phenomenon after primary percutaneous coronary intervention (PPCI) is associated with a poor short-term and long-term clinical prognosis of ST-elevation myocardial infarction (STEMI). Although the increasing use of primary drug-eluting stent (DES) deployment for STEMI resulted in reduced adverse clinical outcomes, the prevalence of no-reflow has been unchanged. The purpose of our study was to evaluate the predictors for no-reflow for STEMI and identify such high-risk patients in the DES era. Methods: The study prospectively enrolled 300 consecutive STEMI patients (80{\%} men; 57 ± 11 years) who underwent PPCI within 12 h of symptom onset. The no-reflow phenomenon was defined as an angiographic outcome of Thrombolysis In Myocardial Infarction (TIMI) grade < 3 without accompanying mechanical factors. Results: Compared to normal reflow patients, no-reflow patients (n = 15, 5{\%} of the total study population) were older (64 ± 13 vs. 57 ±11 years; P = 0.019), transferred to hospital later (7.1 ± 3.2 vs. 4.5 ± 3.8 h; P = 0.011), and had a higher TIMI risk score (5.5 ± 2.0 vs. 3.8 ± 2.2; P = 0.004). B-type natriuretic peptide (BNP), high sensitivity C-reactive protein, and serum creatinine levels were higher in the no-reflow than the normal reflow group. Multivariate analysis (including clinical, angiographic and procedural variables with a P < 0.2 in univariate analysis) showed that high BNP level on admission was the only independent predictor of no-reflow. The area under the receiver-operating characteristics curve analysis value for BNP was 0.786. BNP ≥ 90 pg/ml showed a sensitivity of 80{\%} and a specificity of 70{\%} for predicting no-reflow after primary DES implantation (OR 14.953, 95{\%} CI 3.131-71.419, P = 0.001). Conclusions: Angiographic 'no-reflow' phenomenon after primary DES implantation for STEMI can be predicted by BNP levels on admission. BNP-guided approach may be useful in identifying patients at high risk of the no-reflow phenomenon after primary stenting.",
author = "Jeong, {Young Hoon} and Kim, {Won Jang} and Park, {Duk Woo} and Choi, {Bong Ryong} and Lee, {Seung Whan} and Kim, {Young Hak} and Lee, {Cheol Whan} and Myeongki Hong and Kim, {Jae Joong} and Park, {Seong Wook} and Park, {Seung Jung}",
year = "2010",
month = "5",
day = "28",
doi = "10.1016/j.ijcard.2008.11.189",
language = "English",
volume = "141",
pages = "175--181",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction. / Jeong, Young Hoon; Kim, Won Jang; Park, Duk Woo; Choi, Bong Ryong; Lee, Seung Whan; Kim, Young Hak; Lee, Cheol Whan; Hong, Myeongki; Kim, Jae Joong; Park, Seong Wook; Park, Seung Jung.

In: International Journal of Cardiology, Vol. 141, No. 2, 28.05.2010, p. 175-181.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction

AU - Jeong, Young Hoon

AU - Kim, Won Jang

AU - Park, Duk Woo

AU - Choi, Bong Ryong

AU - Lee, Seung Whan

AU - Kim, Young Hak

AU - Lee, Cheol Whan

AU - Hong, Myeongki

AU - Kim, Jae Joong

AU - Park, Seong Wook

AU - Park, Seung Jung

PY - 2010/5/28

Y1 - 2010/5/28

N2 - Background: The angiographic 'no-reflow' phenomenon after primary percutaneous coronary intervention (PPCI) is associated with a poor short-term and long-term clinical prognosis of ST-elevation myocardial infarction (STEMI). Although the increasing use of primary drug-eluting stent (DES) deployment for STEMI resulted in reduced adverse clinical outcomes, the prevalence of no-reflow has been unchanged. The purpose of our study was to evaluate the predictors for no-reflow for STEMI and identify such high-risk patients in the DES era. Methods: The study prospectively enrolled 300 consecutive STEMI patients (80% men; 57 ± 11 years) who underwent PPCI within 12 h of symptom onset. The no-reflow phenomenon was defined as an angiographic outcome of Thrombolysis In Myocardial Infarction (TIMI) grade < 3 without accompanying mechanical factors. Results: Compared to normal reflow patients, no-reflow patients (n = 15, 5% of the total study population) were older (64 ± 13 vs. 57 ±11 years; P = 0.019), transferred to hospital later (7.1 ± 3.2 vs. 4.5 ± 3.8 h; P = 0.011), and had a higher TIMI risk score (5.5 ± 2.0 vs. 3.8 ± 2.2; P = 0.004). B-type natriuretic peptide (BNP), high sensitivity C-reactive protein, and serum creatinine levels were higher in the no-reflow than the normal reflow group. Multivariate analysis (including clinical, angiographic and procedural variables with a P < 0.2 in univariate analysis) showed that high BNP level on admission was the only independent predictor of no-reflow. The area under the receiver-operating characteristics curve analysis value for BNP was 0.786. BNP ≥ 90 pg/ml showed a sensitivity of 80% and a specificity of 70% for predicting no-reflow after primary DES implantation (OR 14.953, 95% CI 3.131-71.419, P = 0.001). Conclusions: Angiographic 'no-reflow' phenomenon after primary DES implantation for STEMI can be predicted by BNP levels on admission. BNP-guided approach may be useful in identifying patients at high risk of the no-reflow phenomenon after primary stenting.

AB - Background: The angiographic 'no-reflow' phenomenon after primary percutaneous coronary intervention (PPCI) is associated with a poor short-term and long-term clinical prognosis of ST-elevation myocardial infarction (STEMI). Although the increasing use of primary drug-eluting stent (DES) deployment for STEMI resulted in reduced adverse clinical outcomes, the prevalence of no-reflow has been unchanged. The purpose of our study was to evaluate the predictors for no-reflow for STEMI and identify such high-risk patients in the DES era. Methods: The study prospectively enrolled 300 consecutive STEMI patients (80% men; 57 ± 11 years) who underwent PPCI within 12 h of symptom onset. The no-reflow phenomenon was defined as an angiographic outcome of Thrombolysis In Myocardial Infarction (TIMI) grade < 3 without accompanying mechanical factors. Results: Compared to normal reflow patients, no-reflow patients (n = 15, 5% of the total study population) were older (64 ± 13 vs. 57 ±11 years; P = 0.019), transferred to hospital later (7.1 ± 3.2 vs. 4.5 ± 3.8 h; P = 0.011), and had a higher TIMI risk score (5.5 ± 2.0 vs. 3.8 ± 2.2; P = 0.004). B-type natriuretic peptide (BNP), high sensitivity C-reactive protein, and serum creatinine levels were higher in the no-reflow than the normal reflow group. Multivariate analysis (including clinical, angiographic and procedural variables with a P < 0.2 in univariate analysis) showed that high BNP level on admission was the only independent predictor of no-reflow. The area under the receiver-operating characteristics curve analysis value for BNP was 0.786. BNP ≥ 90 pg/ml showed a sensitivity of 80% and a specificity of 70% for predicting no-reflow after primary DES implantation (OR 14.953, 95% CI 3.131-71.419, P = 0.001). Conclusions: Angiographic 'no-reflow' phenomenon after primary DES implantation for STEMI can be predicted by BNP levels on admission. BNP-guided approach may be useful in identifying patients at high risk of the no-reflow phenomenon after primary stenting.

UR - http://www.scopus.com/inward/record.url?scp=77952238236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952238236&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2008.11.189

DO - 10.1016/j.ijcard.2008.11.189

M3 - Article

VL - 141

SP - 175

EP - 181

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 2

ER -